Restriction of Access to Deep Brain Stimulation for Refractory OCD: Failure to Apply the Federal Parity Act

Rachel A. Davis, James Giordano, D. Brian Hufford, Sameer A. Sheth, Peter Warnke, Alik S. Widge, R. Mark Richardson, Joshua M. Rosenow, Peter Justin Rossi, Eric A. Storch, Helena Winston, Jo Anne Zboyan, Darin D. Dougherty, Kelly D. Foote, Wayne K. Goodman, Nicole C.R. McLaughlin, Steven Ojemann, Steven Rasmussen, Aviva Abosch, Michael S. Okun

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish (US)
Article number706181
JournalFrontiers in Psychiatry
Volume12
DOIs
StatePublished - Aug 12 2021

Bibliographical note

Funding Information:
The authors thank members of the University of Colorado Anschutz Research Ethics Team for reviewing this commentary and providing insightful feedback: Jacqueline J, Glover, Ph.D., Marilyn Coors, Ph.D., and Barbara Hammack, Ph.D. Funding. The open access fee will be supported by the University of Colorado Anschutz Department of Psychiatry Growth and Development Funds.

Funding Information:
The open access fee will be supported by the University of Colorado Anschutz Department of Psychiatry Growth and Development Funds.

Funding Information:
Conflict of Interest: RD provides ad hoc paid consulting for Medtronic, Inc. She is PI on COMIRB 14-0554: Reclaim©R Deep Brain Stimulation Therapy for OCD, and DBS for OCD is ∼10% of her clinical practice. RD is a PI (mPI) on the NIH BRAIN RF1 MH121362. She has served on a BrainsWay TMS advisory panel. JG work is supported in part by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Leadership Initiatives, NeurGen, BNB corporation, and the Creighton University Medical Visiting Professorship and receives federal funds from the National Center for Advancing Translational Sciences through the Clinical and Translational Science Awards Program, part of the Roadmap Initiative, Re-Engineering the Clinical Research Enterprise. DH is head of the health insurance litigation practice of Zuckerman Spaeder LLP, where he represents patients and providers in disputes with health insurance companies and claims administrators. He led the team that brought the Wit v. United Behavioral Health litigation. SS receives research support from the NIH, McNair Foundation, and Dana Foundation. He is a consultant for Boston Scientific, Zimmer Biomet, Neuropace, Koh Young, and Abbott. PW receives Research Funding though the NIH Brain Initiative and Medtronic. PW is Associate Editor Journal of Neurology, Neurosurgery and Psychiatry. AW has received support from the Minnesota’s Discovery, Research, and InnoVation Economy (MnDRIVE) initiative, the Minnesota Medical Discovery Team on Addictions, and NIH; he has received device donations from Medtronic; he has served as a consultant for Circuit Therapeutics, Cyberonics, and Medtronic; and he has multiple patent applications in the area of brain stimulation and circuit modification to improve cognition. RR has received consulting and speaker fees from Medtronic. JR reports grants and personal fees from Boston Scientific. ES receives support from the NIMH RF1 MH121371 grant. WG reports grants from NIH, Biohaven Pharmaceutics, IOCDF, McNair Foundation and non-financial support from Medtronic, personal fees from Biohaven. DD has received honoraria, consultation fees and/or royalties from Medtronic. KF reports grants from NIH, and other funding from Donnellan/Einstein/Merz Chair; grants and non-financial support from Medtronic, grants from St Jude, Functional Neuromodulation, and Boston Scientific, and grants and other funding from Neuropace. Additionally, KF has a patent US 8295935 B2 issued for a DBS cranial lead fixation device. NM receives research funding through NIH (P20GM130452; P50MH106435). MO serves as a consultant for the Parkinson’s Foundation, and has received research grants from NIH, Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. MO’s DBS research is supported by: NIH R01 NR014852 and R01NS096008. MO is PI of the NIH R25NS108939 Training Grant. MO has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge (movement disorders books). MO is an associate editor for New England Journal of Medicine Journal Watch Neurology. MO has participated in CME and educational activities on movement disorders sponsored by the Academy for Healthcare Learning, PeerView, Prime, QuantiaMD, WebMD/Medscape, Medicus, MedNet, Einstein, MedNet, Henry Stewart, American Academy of Neurology, Movement Disorders Society and by Vanderbilt University. The institution and not MO receives grants from Medtronic, Abbvie, Boston Scientific, Abbott and Allergan and the PI has no financial interest in these grants. MO has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. Research projects at the University of Florida receive device and drug donations.

Keywords

  • OCD
  • advocacy
  • deep brain stimulation
  • health insurance
  • mental health parity
  • neuromodulation
  • obsessive-compulsive disorder

PubMed: MeSH publication types

  • Journal Article

Cite this